Abstract: Provided are methods for preventing and treating injuries caused by exposure to biological warfare agents. The methods include administering to a subject in need thereof an effective amount of a TRPA1 antagonist or a pharmaceutically acceptable salt thereof. In an embodiment the TRPA1 antagonist is selected from the group consisting of compounds of formula I and compounds of formula II as described herein.
Abstract: The invention provides novel compositions and compounds that inhibit CatSper channel activity, that preferentially inhibits sperm hyperactivity over sperm motility, or both. The compounds of the invention are useful as contraceptive agents that may be adminstered to males, females, or concurrently to both sexual partners. The invention further provides methods of conducting drug discovery business and of conducting a reproductive medicine business. The invention also provides methods of identifying compounds that modulate sperm hypermotility.
Abstract: The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.
Type:
Grant
Filed:
January 29, 2013
Date of Patent:
November 10, 2015
Assignee:
HYDRA BIOSCIENCES, INC.
Inventors:
Magdalene M. Moran, Jayhong A. Chong, Christopher Fanger, Amy S. Ripka, Glenn R. Larsen, Xiaoguang Zhen, Dennis John Underwood, Manfred Weigele
Abstract: The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.
Type:
Application
Filed:
November 14, 2014
Publication date:
October 22, 2015
Applicant:
HYDRA BIOSCIENCES, INC.
Inventors:
Jayhong A. Chong, Christopher Fanger, Glenn R. Larsen, William C. Lumma, JR., Magdalene M. Moran, Amy Ripka, Dennis John Underwood, Manfred Weigele, Xiaoguang Zhen, Anu Mahadevan, Peter Meltzer
Abstract: Methods of treating a TRPC5 mediated disorder in a subject by administering an effective amount of a TRPC5 antagonist, such as a compound disclosed herein, are described.
Type:
Grant
Filed:
December 10, 2013
Date of Patent:
September 22, 2015
Assignee:
HYDRA BIOSCIENCES, INC.
Inventors:
Jayhong A. Chong, Christopher Fanger, Magdalene M. Moran, Elisha Singer, Timothy Strassmaier, Howard Ng
Abstract: The invention provides novel compositions and compounds that inhibit CatSper channel activity, that preferentially inhibits sperm hyperactivity over sperm motility, or both. The compounds of the invention are useful as contraceptive agents that may be adminstered to males, females, or concurrently to both sexual partners. The invention further provides methods of conducting drug discovery business and of conducting a reproductive medicine business. The invention also provides methods of identifying compounds that modulate sperm hypermotility.
Abstract: The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.
Type:
Grant
Filed:
November 15, 2006
Date of Patent:
December 23, 2014
Assignee:
Hydra Biosciences, Inc.
Inventors:
Jayhong A. Chong, Christopher Fanger, Glenn R. Larsen, William C. Lumma, Jr., Magdalene M. Moran, Amy Ripka, Dennis John Underwood, Manfred Weigele, Xiaoguang Zhen, Anu Mahadevan, Peter Meltzer
Abstract: The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.
Type:
Application
Filed:
August 30, 2013
Publication date:
June 5, 2014
Applicant:
HYDRA BIOSCIENCES, INC.
Inventors:
Jayhong A. Chong, Christopher Fanger, Glenn R. Larsen, William C. Lumma, JR., Anu Mahadevan, Peter Meltzer, Magdalene M. Moran, Amy Ripka, Dennis Underwood, Manfred Weigele, Xiaoguang Zhen
Abstract: Methods of treating a TRPC5 mediated disorder in a subject by administering an effective amount of a TRPC5 antagonist, such as a compound disclosed herein, are described.
Type:
Application
Filed:
December 10, 2013
Publication date:
April 10, 2014
Applicant:
HYDRA BIOSCIENCES, INC.
Inventors:
Jayhong A. Chong, Christopher Fanger, Magdalene M. Moran, Elisha Singer, Timothy Strassmaier, Howard Ng